Therapeutic Innovation & Regulatory Science Template
Write in a clean editor, then format for Therapeutic Innovation & Regulatory Science in one click — DocuGuru applies the official Springer Nature template with superscript references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the Therapeutic Innovation & Regulatory Science format
Therapeutic Innovation & Regulatory Science is a peer-reviewed journal published by Springer Nature, covering Health Systems, Economic Evaluations, Quality of Life, Statistical Methods in Clinical Trials, Pharmaceutical Economics and Policy.
| Publisher | Springer Nature |
|---|---|
| Reference style | Superscript numbered (Nature) Superscript — small raised numerals in the text 1. Smith, A., Jones, B. & Lee, C. A representative article title. Therapeutic Innovation & Regulatory Science 12, 45–58 (2023).
Formats any DOI in Therapeutic Innovation & Regulatory Science style. No sign-up. |
| Publishes research in | Health Systems, Economic Evaluations, Quality of Life Statistical Methods in Clinical Trials Pharmaceutical Economics and Policy Biomedical Ethics and Regulation Ethics in Clinical Research |
| ISSN | 2168-4790 |
| Citation impact (2-yr) | 1.82 |
| h-index | 49 |
| i10-index | 454 |
| Total citations | 15,998 |
| Article processing charge | $3,590 |
| Top institutions publishing here | United States Food and Drug Administration |
| Journal website | www.springer.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in Therapeutic Innovation & Regulatory Science per year
Citation impact of Therapeutic Innovation & Regulatory Science by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in Therapeutic Innovation & Regulatory Science
BACKGROUND: While patient groups, regulators, and sponsors are increasingly considering engaging with patients in the design and conduct of clinical development programs, sponsors are often reluctant to go beyond pilot programs because of uncertainty in the return on investment. We developed an approach to estimate the financial value of patient engagement. METHODS: Expected net present…
The regulatory standards of the United States Food and Drug Administration (FDA) require substantial evidence of effectiveness from adequate and well-controlled trials that typically use a valid comparison to an internal concurrent control. However, when it is not feasible or ethical to use an internal control, particularly in rare disease populations, relying on external controls…